Patents by Inventor Marie TÖRNGREN

Marie TÖRNGREN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPY
    Publication number: 20230085883
    Abstract: A combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and at least one further compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody, for use as a in the treatment of multiple myeloma. A kit comprising tasquinimod and a package insert with instructions for using tasquinimod in combination with at least one further compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody, to treat multiple myeloma in an individual. Tasquinimod for use in the treatment of multiple myeloma, in combination with a further compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody.
    Type: Application
    Filed: March 3, 2021
    Publication date: March 23, 2023
    Inventors: Yuliya NEFEDOVA, Marie TÖRNGREN, Helena ERIKSSON, Dmitry GABRILOVICH, Fabien SCHMIDLIN
  • Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation
    Publication number: 20230066364
    Abstract: The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
    Type: Application
    Filed: September 7, 2022
    Publication date: March 2, 2023
    Applicant: Active Biotech AB
    Inventors: Helena Eriksson, Joel Kaye, Marie Törngren
  • Compounds for treatment of eye diseases associated with excessive vascularisation
    Patent number: 11478465
    Abstract: The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: October 25, 2022
    Assignee: Active Biotech AB
    Inventors: Helena Eriksson, Joel Kaye, Marie Törngren
  • Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation
    Publication number: 20210322400
    Abstract: The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 21, 2021
    Applicant: Active Biotech AB
    Inventors: Helena Eriksson, Joel Kaye, Marie Törngren
  • Quinoline carboxamides for use in the treatment of leukemia
    Patent number: 10300053
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of leukemia.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: May 28, 2019
    Assignee: ACTIVE BIOTECH AB
    Inventors: Helena Eriksson, Leif Svensson, Marie Törngren
  • QUINOLINE CARBOXAMIDES FOR USE IN THE TREATMENT OF LEUKEMIA
    Publication number: 20170319568
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of leukemia.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 9, 2017
    Applicant: Active Biotech AB
    Inventors: Helena ERIKSSON, Leif SVENSSON, Marie TÖRNGREN